Patheon and PROCAPS S.A. have announced an agreement to provide the pharmaceutical industry a new world-class line of prescription pharmaceutical soft-gel product development and manufacturing services. The offering will be branded as “P-Gels” soft gels and the partnership will give Patheon rights to market PROCAPS’ soft gel technology and manufacturing capabilities in North America, Europe and Asia. The capabilities the company gains via the P-Gels offering include large-scale commercial supply of prescription soft gel capsules for the North American, European and Asian markets. PROCAPS has been developing and manufacturing soft gel capsules since 1977 and currently has capacity to manufacture up to nine billion capsules per year. The soft gel dosage form provides important advantages for drug delivery and consumer experience. It offers rapid and consistent absorption of drugs and consistent delivery of highly potent drugs that require small dosages. In many cases, soft gels can be used to improve the solubility of drugs that pose bioavailability challenges. Consumer advantages include reliable delivery, taste masking, ease of swallowing and rapid onset.
Patheon Inc., Research Triangle Park, NC 27709. www.patheon.com or call 919-226-3200
INTERPHEX 2012 Booth No. 1418
